StockData

InnovAge vs GeneDx

INNV and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INNV and WGS compare

GeneDx is the larger company, worth 1.2 times as much as InnovAge ($1.5B against $1.3B).

GeneDx grew revenue faster over the last twelve months (25.4% versus 15.9% for InnovAge).

InnovAge keeps more of each dollar of sales as profit, with a net margin of −0.26% compared with −23.4% at GeneDx.

InnovAge scores higher on the StockData Score (11 against 6 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINNVWGS
Size and price
Market cap$1.3B$1.5B
Share price$9.42$51.02
Change, 1 year94.6%−60.9%
Change, 5 years23.8%−77.6%
Beta (5Y)−0.150.82
Employees2,5001,300
StockData Score
Total score11 (better)6
Valuation score00
Growth score33
Performance score3 (better)1
Health score5 (better)2
Dividend score00
Valuation
P/S1.3× (better)3.3×
P/B5.5× (better)6.2×
EV/EBITDA50.3×–
P/FCF25.5×–
FCF yield3.9% (better)−5.0%
Fair value$5.76$32.23
Margin of safety−63.5%−58.3% (better)
Growth
Revenue growth (TTM)15.9%25.4% (better)
Revenue growth, 5Y average9.2%19.0% (better)
Net income growth (TTM)–−7665%
EPS growth (TTM)–−18300%
Profitability
Gross margin23.0%69.4% (better)
Operating margin0.26% (better)−20.3%
Net margin−0.26% (better)−23.4%
FCF margin5.1% (better)−16.7%
Return on equity−1.1% (better)−40.8%
Return on invested capital1.2% (better)−36.2%
Financial health
Debt / equity0.20 (better)0.40
Net debt / EBITDA−3.93–
Current ratio1.053.30 (better)
Altman Z-score4.22 (better)0.36
Piotroski F-score66
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions13.5%107%
Held by insiders75.4%–
Insider net buying, 12 months−$227M$91.2M (better)
Short interest, % of float2.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.